Abzena

Abzena

Pharmaceutical Manufacturing

San Diego, California 22,806 followers

Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward.

About us

Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.

Website
http://www.abzena.com
Industry
Pharmaceutical Manufacturing
Company size
501-1,000 employees
Headquarters
San Diego, California
Type
Privately Held
Founded
2001
Specialties
Immunogenicity Assessment & Protein Engineering, Cell Line Development to GMP Manufacturing, ADCs & GMP Bioconjugation, Custom Chemical Synthesis, Analytical and Bioassay Solutions, Linker Payloads, Pre-Formulation, Process Development, Technology Transfer, Integrated Drug Development and Manufacturing Programs, and Analytical Method Development

Locations

Employees at Abzena

Updates

  • View organization page for Abzena, graphic

    22,806 followers

    In our continued celebration of World Quality Month, Dr Louise Duffy, our Chief Technical and Quality Officer, shares her thoughts on elevating quality to the next level across everything we do at Abzena. Louise emphasizes to our team that every action we take has a quality impact. Working on highly complex molecules at the cutting-edge of design and development presents unique technical challenges. Hear how Louise reminds us of our critical role in delivering these next-gen therapeutics to improve patient lives. #WorldQualityMonth #QualityExcellence #DrugDevelopment #QualityAndCompliance #CDMO #CRO

  • View organization page for Abzena, graphic

    22,806 followers

    At BEBPA, we presented a poster entitled, "Streamlining the Development of Relative Potency Assays for ADCs." The poster delved into the essential role that relative potency assays play in maintaining the efficacy and potency of biologics throughout their lifecycle.   This work focused on designing bespoke assays tailored to the complex mechanisms of action (MoAs) of antibody-drug conjugates (ADCs). These assays encompass critical steps in ADC functionality, including target binding, internalization, intracellular payload release, and tumor cell elimination. By comprehensively addressing these processes, we can develop robust, regulatory-compliant assays that support ADC development from early-stage research through clinical trials.   Access the full poster here: https://lnkd.in/eqbh8WiZ   #ADCCRO #ADCCDMO #Bioassay #PotencyAssays #DrugDevelopment

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    Last chance to register! Join our #webinar with Promega UK today at 3pm GMT / 10am EST entitled: "Always Look on the Bright Side of (Cell) Death: Cytotoxicity Assays for Antibody Drug Conjugate Development." Hear from Abzena’s experts, Grant Harradence & Robert J Francis PhD FRMS, as they discuss how advanced bioassays are driving innovation in antibody-drug conjugate (ADC) development. This webinar will explore how Abzena applies developability principles throughout the drug development process. Using two approved ADCs as examples, our speakers will demonstrate the robustness of bioassays in 3D cell culture models and highlight biological methods that support lead candidate selection for further discovery.   Register now to discover how Abzena & Promega's expertise can help advance your ADC: https://bit.ly/4hRF7mP #ADCCRO #drugdevelopment #bioconjugates #CDMO https://lnkd.in/gGrgftX8  

    View organization page for Promega UK, graphic

    2,057 followers

    Don't forget to join us tomorrow, Wednesday 20 November 2024 at 3.00pm (GMT) for our free webinar - Always Look on the Bright Side of (Cell) Death: Cytotoxicity Assays for Antibody Drug Conjugate Development. In this webinar you will learn: • The benefits of drug screening in 3D cell cultures and how using optimised 3D cell-based assays address the challenges of measuring cell health in 3D cultures, leading to more effective assessment of key outcomes, such as viability and apoptosis. • The role of bioassays in ADC developability and lead selection • How complex co-culture and 3D in vitro models enable researchers to select the best candidate to take forward for clinical development Your presenters will be: o Darren Heywood, Product Manager, Cell Health, Promega UK o Grant Harradence, Manager, Abzena o Robert Francis, PhD, Manager & Microscopy Lead, Abzena Abzena is a leading biopharmaceutical CDMO and CRO offering fully integrated, customised drug development and manufacturing services from early discovery to clinical trials. In this webinar, Darren Heywood from Promega will introduce plate-based cell health assays for drug development and screening in 3D cell cultures. Register at https://bit.ly/4hRF7mP #HTS #3DCellCulture #CellHealth

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    NEWS: We are thrilled to announce the expansion of our early and late-phase analytical capabilities to now include #GMP cell-based potency assays at our Cambridge, UK and San Diego, CA development and manufacturing facilities. GMP cell-based potency assays play an essential role in quantitatively measuring the biological activity of a biopharmaceutical, and the cytotoxicity of the payload of an Antibody-drug conjugate (ADC), for both GMP product release and stability testing.  Our CSO, Campbell Bunce PhD MBA shares, "Our established expertise and reputation have allowed us to extend our early-phase capabilities to include GMP cell-based potency services at our global sites, addressing a critical need for our customers. This significant milestone further demonstrates our commitment to providing comprehensive, end-to-end support for our customer’s next-generation programs that drive successful outcomes from discovery to the clinic and onwards towards commercial.” Read the full press release here: https://lnkd.in/gM6mEzgd #drugdevelopment #CDMO #CRO #biopharmaceuticals #analytical #bioassays

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    Philadelphia has a rich history of drug development and manufacturing innovations which support its reputation as a life sciences hub. In a recent BioBuzz feature, Abzena was highlighted as one of the city's prominent CDMOs, for our ongoing contributions to the region, including a $5 million investment in our Bristol, PA facility to enhance bioconjugation and ADC manufacturing capabilities.   The investment included expanded QC and analytical laboratory space, new chromatography and purification equipment, and facility upgrades. These additions further enhanced the site's existing bioconjugation capabilities and increased its capacity to support the delivery of fully integrated biopharmaceutical drug programs.   Learn more about how Abzena is driving bioconjugate innovation in the Philadelphia area: https://lnkd.in/eZXADjiF   #CDMO #ADCCDMO #ADCDevelopment #Bioconjugation #DrugSubstance

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    Developing a reliable and scalable cGMP manufacturing process for biologics can be complex, often encountering challenges such as process variability, scalability limitations, and stringent regulatory requirements. These obstacles can disrupt clinical and commercial timelines, jeopardizing program success.   At Abzena, we deliver Clinical to Commercial cGMP biologics manufacturing with a flexible and tailored approach designed to address the unique requirements of your diverse biologic modality. Our comprehensive technology transfer program ensures seamless scale-up by integrating advanced process control and optimization strategies, resulting in robust and consistent manufacturing outcomes.   With deep expertise in process characterization and validation, lifecycle management, and regulatory compliance, we work as an extension of your team to navigate complex manufacturing challenges, mitigate risks, and accelerate the path through commercialization.   Discover how Abzena’s expertise can optimize the manufacturing of your biologic today: https://lnkd.in/eHxGADyN #BiologicsManufacturing #cGMP #DrugDevelopment #CDMO #Biotechnology

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    In celebration of World Quality Month, the Abzena team is spreading the word about our unwavering commitment to Quality and Compliance. As our Head of Global Quality, Troy Wright, shares, "Quality is the heart of everything we do—from developing safe, effective products to building trusted client partnerships worldwide."   Quality isn’t just a standard; it’s a promise we bring to every drug development project and interaction, continuously raising the bar in the biopharmaceutical CDMO and CRO space. This dedication defines Abzena as a trusted leader, known for reliability, innovation, and excellence in every endeavor.   Hear what Troy shared with our team to excite and inspire them about such an important core value to our organization. Happy Quality Month!   #WorldQualityMonth #QualityExcellence #DrugDevelopment #QualityAndCompliance #CDMO #CRO

  • View organization page for Abzena, graphic

    22,806 followers

    Avacta Therapeutics recently presented a poster we collaborated on at EORTC-NCI-AACR 2024 entitled, "Affimer® Drug Conjugates Targeting Fibroblast Activation Protein-α." The poster highlights AffDCs as an innovative therapeutic class designed to deliver potent warheads with remarkable precision.   Using the pre|CISION® release mechanism, these #AffDCs are activated only within the tumor microenvironment through FAP-specific cleavage. This ensures that the toxic payloads are delivered directly to cancer cells, sparing healthy tissues and enhancing tumor penetration. The poster also details how the smaller Affimer® proteins enable effective tumor targeting and robust bystander effects, advancing the promise of targeted biotherapeutics in oncology.   Access the poster here: https://lnkd.in/gQ25pYUu #CancerResearch #OncologyInnovation #Biotherapeutics #CDMO #CRO #TargetedTherapy

    • No alternative text description for this image
  • View organization page for Abzena, graphic

    22,806 followers

    At PEGS Europe last week, our Manager of Protein Engineering, Dr. Christopher Sayer caught up with Life Science Blogger, Rizwan Chaudhrey to share valuable insights into what sets Abzena apart in the field of bispecific therapeutic antibodies.   Chris also discussed his presentation on "Detection and Correcting of Antibody Imperfections," and poster on bispecific development techniques which highlighted our unique approach for tackling the challenges in developing these complex biologics.   Tune in to learn more about how Abzena is accelerating #antibody development and partnering with customers to bring innovative therapies from concept to clinic.   Watch the interview here: https://lnkd.in/e3v_eAt4    #AntibodyEngineering #DrugDevelopment #Biologics #CDMO #CRO

  • View organization page for Abzena, graphic

    22,806 followers

    In a recent Outsourcing-Pharma interview, Abzena's CSO, Campbell Bunce PhD MBA shared insights into what we were planning to showcase at CPHI in Milan. From our latest innovations in cell line development with our newly enhanced AbZelectPRO™ platform to our next-gen ADC linker technology, ThioBridge™, he shares how our comprehensive and integrated solutions are streamlining drug development processes and minimizing risks for our customers.    The AbZelectPRO™ platform enables customers to go from DNA to research cell bank (RCB) in just 10 weeks, producing 8g/L of stable clones. This high-producing and highly stable platform offers quicker doubling times and an optimized expression cassette that’s proven to enhance protein expression by leveraging novel genetic elements, leading to improved production levels across a wide range of protein targets, including difficult-to-express proteins such as bi-specifics and fusion proteins.   Abzena also showcased its high-potency handling capabilities for the development and cGMP manufacture of ADCs, along with its next-generation site-specific linker technology, ThioBridge™. This cutting-edge technology allows precise, site-specific conjugation, ensuring superior control over drug-antibody ratios (DAR) and enhanced ADC stability. By consolidating linker-payload design, conjugation, and cGMP manufacturing within a single organization, Abzena minimizes supply chain complexity and accelerates timelines, providing substantial value for our customers.   Access the full interview to learn more about our commitment to advancing drug development: https://lnkd.in/epVhQxQa   #DrugDevelopment #ADCDevelopment #Bioconjugation #CellLineDevelopment #CDMO #CRO

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Abzena 5 total rounds

Last Round

Private equity

US$ 65.0M

See more info on crunchbase